



Phone: 386-957-9600 Fax: 386-957-9400

## (Donanemab-azbt) Infusion Order

**PATIENT INFORMATION:** 

Patient Name:		
OB: Phone number:		
Allergies: ☐ NKDA ☐ allergic to		
□ start new treatment □ continue	treatment d	ose/s already complete. Date of last dose:
Height: Weight:		CMS Submission #:
DIAGNOSIS:		
☐ G30.0- AD w/ early onset ☐ G30 ☐ G31.84- MCI, so stated PREMEDICATION & HYDRATION:		et □G30.8- other AD □G30.9- AD unspecified
☐ Diphenhydramine 25 mg IVP O	<b>R</b> Diphenhydramin	ne 25 mg PO <u>OR</u> Citirizine 10 mg PO
□ acetaminophen 1000 mg PO □ Solu Medrol 125 mg IVP □ 500 ml hydration over 30 minutes		
REQUIRED TESTING/LABS		
*MRI prior to initiating treat prior to 2nd, 3rd, 4th, and 7 *PET Scan *Patients last visit note		*Clinical notes with amyloid beta confirmation *APOe3 testing- optional *MoCA or MMSE
KISUNLA DOSING:		-
☐ 350 mg at infusion #1, 700 mg finfusion #4 and beyond	or infusion #2, 105	0 for infusion #3 ☐ 1400 mg every 4 weeks for
★ Patient takes anticoagulants and provider has approved Kisunla treatment □ yes □ no		
★ If <u>yes</u> , has provider discussed	I risk of ARIA with I	patient □yes □no
ORDERING PROVIDER:		
Name:		NPI
Phone:	fa>	K:
Practice Address:	State	Zip:
	0.0.0.	
Provider Signature		Date: